Eighty-one panic disorder patients with or without agoraphobia were treated with flexible doses of clomipramine under single-blind conditions. Fifty-seven (70.3%) reached operational criteria for full remission in 16.2 ± 6.5 weeks, with a mean dose of 89.1 ± 8.2 mg/day. Fifty-four (81%) of them received a continuous post-remission maintenance treatment at full doses of clomipramine for 4–6 months. No patient relapsed during the clomipramine maintenance phase. Their medication was then tappered and discontinued with placebo substitution under double-blind conditions. Fifty-one (63%) patients were followed-up until relapse or recurrence for up to 3 years, with periodic assessments. Three different outcome groups were identified: the first (n = 19, 19; 37.2%) experienced an early/immediate relapse (5.2 ± 4.9 weeks after drug discontinuation); the second group (n= 22, 22; 43.1%) experienced recurrence after 42.9 ± 35 weeks following discontinuation; and the third group (n = 10, 10; 19.6%) remained assymptomatic and functionally well throughout the follow-up. Predictors of early relapse were: (1) higher baseline score in the Beck Depression Inventory; (2) higher global score on the phobic avoidance scale after the full remission criteria; and (3) the need for higher clomipramine doses to reach full remission. The need for long-term or intermittent maintenance for most patients is emphasized.
Albus M, Scheibe G (1993) Outcome of panic disorder with or without concomitant depression: a 2-year prospective follow-up study. Am J Psychiatry150: 1878–1880
2.
American Psychiatric Association (1987) Diagnostic and statistical manual of mental disorders, 3rd rev. edn.American Psychiatric Association, Washington, DC
3.
Ballenger J C (1992) Medication discontinuation in panic disorder. J Clin Psychiatry53(Suppl.): 26–31
4.
Ballenger J C (1993) Panic disorder: efficacy of current treatments. Psychopharmacol Bull29: 477–486
5.
Ballenger J C, Pecknold J, Rickels K, Sellers E M (1993) Medication discontinuation in panic disorder. J Clin Psychiatry54: 15–24
6.
Bakker A, van Balkom AJ, Spinhoven P, Blaauw B M, van Dyck R (1998) Follow-up on the treatment of panic disorder with or without agoraphobia: a quantitative review. J Nerv Ment Dis186: 414–419
7.
Beck A T, Ward C, Mendelson M, Mock J, Erbaugh J (1961) An inventory for measuring depression. Arch Gen Psychiatry4: 561–571
8.
Black D W, Wesner R B, Gabel J, Bowers W, Monahan P (1994) Predictors of short-term treatment response in 66 patients with panic disorder. J Affect Disord30: 233–241
9.
Burrows G D, Judd F K, Norman T R (1993) Long-term drug treatment of panic disorder. J Psychiatr Res27 (Suppl. 1): 111–125
10.
Dager S R, Khan A, Cowley D, Avery D H, Elder J, Roy-Byrne P, Dunner D L (1990) Characteristics of placebo response during long-term treatment of panic disorder. Psychopharmacol Bull26: 273–278
11.
Delgado P L, Gelenberg A J (1995) Antidepressant and antimanic medications. In Gabbard G O (ed.), Treatments of psychiatric disorders, vol. 1, pp. 1131–1168. American Psychiatric Press, Washington DC
12.
Fahy T J, O'Rourke D, Brophy J et al. (1992) The Galway study of panic disorder, I: clomipramine and lofepramine in DSM III-R panic disorder: a placebo controlled trial. J Affect Disord25: 63–76
13.
Feet P O, Gotestam K G (1994) Increased antipanic efficacy in combined treatment with clomipramine and dixyrazine. Acta Psychiatr Scand89: 230–234
14.
Fyer A J, Liebowitz M R, Gorman J M, Campes R, Levin A, Davies S O, Goetz D, Klein D (1987) Discontinuation of alprazolam treatment in panic patients. Am J Psychiatry143: 303–308
15.
Gentil V (1986) Fisiopatologia da síndrome do pânico. Rev Assoc Med Brasil32: 101–107
16.
Gentil V, Lotufo-Neto F, Andrade L, Cordás T, Bernik M, Ramos R, Maciel L, Miyakawa E, Gorenstein C (1993) Clomipramine, a better reference drug for panic/agoraphobia. I. Effectiveness comparison with imipramine. J Psychopharmacol7: 316–324
17.
Gloger S, Grunhaus L, Birmarcher B, Troudart T (1981) Treatment of spontaneous panic attacks with chlomipramine. Am J Psychiatry138: 1215–1217
Gorman J M, Papp L A (1990) Chronic anxiety: deciding the length of treatment. J Clin Psychiatry51(Suppl.): 11–15
20.
Guy W (1976) ECDEU assessment manual for psychopharmacology, rev. edn. NIMH, Bethesda
21.
Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry23: 56–62
22.
Johnston D G, Troyer I E, Whitsett S E (1988) Clomipramine treatment of agoraphobic women. An eight-week controlled trial. Arch Gen Psychiatry45: 453–459
23.
Katschnig H, Amering M, Stolk JM, Klerman GL, Ballenger JC, Briggs A, Buller R, Cassano G, Garvey M, Roth M, Solyom C (1995) Long-term follow-up after a drug trial for panic disorder. Br J Psychiatry167: 487–494
24.
Katschnig H, Amering M (1998) The long-term course of panic disorder and its predictors. J Clin Psychopharmacol18 (Suppl. 2): 6S–15S
25.
Keller M B, Hanks D L (1993) Course and outcome in panic disorder. Prog Neuropsychopharmacol Biol Psychiatry17: 551–570
26.
Keller M B, Yonkers K A, Warshaw M G, Pratt L A, Gollan J K, Massion A O, White K, Swartz A R, Reich J, Lavori P W (1994) Remission and relapse in subjects with panic disorder and panic with agoraphobia. A prospective short-interval naturalistic follow-up. J Nerv Ment Dis182: 290–296
27.
Klein D F (1964) The delineation of two drug-responsive anxiety syndromes. Psychopharmacologia5: 397–408
28.
Kupfer D J (1991) Lessons to be learned from long-term treatment of affective disorders: potential utility in panic disorder. J Clin Psychiatry52(Suppl.): 12–16
29.
Leonard B E (1993) The comparative pharmacology of new antidepressants. J Clin Psychiatry54(Suppl.): 3–15
30.
Maddock R J, Carter C S, Blacker K H, Beitman B D, Krishnan K R, Jefferson J W, Lewis C P, Liebowitz M R (1993) Relationship of past depressive episodes to symptom severity and treatment response in panic disorder with agoraphobia. J Clin Psychiatry54: 88–95
31.
Marks I M, Matthews A M (1979) Brief standard self-rating for phobic patients. Behav Res Therapy17: 263–267
32.
Marks I M, Grey S, Cohen S D, Hill R, Mawson D, Ramm E M, Stern R S (1983) Imipramine and brief therapist-aided exposure in agoraphobics havinng self exposure homework: a controlled trial. Arch Gen Psychiatry40: 153–162
33.
Mavissakalian M, Michelson I (1986) Two-year follow-up of exposure and imipramine treatment of agoraphobia. Am J Psychiatry143: 1106–1112
34.
Mavissakalian M, Perel J M (1992a) Clinical experiments in maintenance and discontinuation of imipramine therapy in panic disorder with agoraphobia. Arch Gen Psychiatry49: 318–323
35.
Mavissakalian M, Perel J M (1992b) Protective effects of imipramine maintenance treatment in panic disorder with agoraphobia. Am J Psychiatry149: 1053–1057
36.
Modigh K, Westberg P, Eriksson E (1992) Superiority of clomipramine over imipramine in the treatment of panic disorder: a placebo controlled trial. J Clin Psychopharmacol12: 251–261
37.
Nagy L M, Kristal J H, Charney D S, Merikangas K R, Woods S W (1993) Long-term outcome of panic disorder after short-term imipramine and behavioral group treatment: 2.9 year naturalistic follow-up study. J Clin Psychopharmacol13: 16–24
38.
Noyes R Jr, Garvey M J, Cook B L, Samuelson L (1989) Problems with tricyclic antidepressant use in patients with panic disorder or agoraphobia: results of a naturalistic follow-up study. J Clin Psychiatry50: 163–169
39.
Noyes R Jr, Perry P (1990) Maintenance treatment with antidepressants in panic disorder. J Clin Psychiatry51(Suppl.): 24–30
40.
Pecknold J C, Swinson R P, Kuch K, Lewis C P (1988) Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. Arch Gen Psychiatry45: 429–436
41.
Pollack M H (1990) Long-term management of panic disorder. J Clin Psychiatry51(Suppl.): 11–13
42.
Pollack M H, Otto M W (1997) Long-term course and outcome of panic disorder. J Clin Psychiatry52(Suppl. 2): 57–60
43.
Ramos R, Gentil V, Gorenstein C (1993) Clomipramine and initial worsening in panic disorder: beyond the ‘jitteriness syndrome’. J Psychopharmacol7: 265–269
44.
Rickels K, Schweizer E (1998) Panic disorder: long-term pharmacotherapy and discontinuation. J Clin Psychopharmacol18(Suppl. 2): 12S–18S
45.
Rickels K, Schweizer E, Weiss S, Zavodnick S (1993) Maintenance drug treatment of panic disorder. II. Short- and long-term outcome after drug taper. Arch Gen Psychiatry50: 61–68
46.
Rosenbaum JF (1997) Treatment of panic disorder: the state of the art. J Clin Psychiatry58(Suppl. 2): 3-3
47.
Roy-Byrne P P, Cowley D S (1995) Course and outcome in panic disorder: a review of recent follow-up studies. Anxiety1: 151–160
48.
Sheehan D V (1983) The anxiety disease. Charles Schriber's Sons, New York
49.
Sheehan D V, Ballenger J, Jacobsen G (1980) Treatment of endogenous anxiety with phobic, hysterical and hypochondriacal symptoms. Arch Gen Psychiatry37: 51–59
50.
Spielberger C D, Gorsuch R L, Lushene R E (1970) Manual for the State-Trait Anxiety Inventory. Consulting Psychologists Press, Palo Alto, CA [Translated to portuguese by Biaggio M B A, Natalício L (1979) Manual para o Inventário de Ansiedade Traço-estado (IDATE). Centro Editor de Psicologia Aplicada – CEPA, Rio de Janeiro
51.
Tyrer P, Owen R, Dawling S (1983) Gradual withdrawal of diazepam after long-term therapy. Lancet1: 1402–1406
52.
Wittchen H U (1988) Natural course and spontaneous remissions of untreated anxiety disorders: results of the Munich follow-up studies. In Hand I, Wittchen H U (eds), Panic and phobias 2: treatments and variables affecting course and outcome, pp. 3–17. Springer-Verlag, Berlin
53.
Zitrin C M, Klein D F, Woerner M G (1980) Treatment of agoraphobia with group exposure in vivo and imipramine. Arch Gen Psychiatry37: 63–72
